-
Mashup Score: 2Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents - 6 month(s) ago
Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 3Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history - 6 month(s) ago
The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease bodyweight and have the potential to counter low-grade inflammation.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents - 7 month(s) ago
Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2β-adrenergic receptors feel the heat against obesity - 7 month(s) ago
Nature Reviews Endocrinology – β-adrenergic receptors feel the heat against obesity
Source: www.nature.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents - 8 month(s) ago
Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 0Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents - 8 month(s) ago
Cardiovascular disease represents a major burden in people with type 2 diabetes, and the prevention of cardiovascular complications has become a main objective when treating at-risk people. Numerous cardiovascular outcome trials (CVOTs) were published in recent years that showed not only the cardiovascular safety, but also the efficacy, of new glucose-lowering therapies. However, almost all CVOTs used a placebo as comparator rather than an active agent, and there were no CVOTs that directly compared the cardiovascular effects between newer glucose-lowering agents—especially SGLT2 inhibitors versus GLP-1 receptor agonists.
Source: www.thelancet.comCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1Shifting Focus on Obesity: Don't Forget About Glucose - 8 month(s) ago
The recent American Diabetes Association meeting largely focused on obesity, leading Anne L. Peters, MD, to stress that glucose continues to matter.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0ENDO 2023 press conferences to highlight emerging technology and diabetes research - 10 month(s) ago
Researchers will delve into the latest research in diabetes, obesity, reproductive health and other aspects of endocrinology during the Endocrine Society’s ENDO 2023 news conferences June 15-18.
Source: www.endocrine.orgCategories: Endocrinology, Latest HeadlinesTweet-
In addition, the #Hormones and #Technology News Conference explores how families of children with #diabetes could be using continuous glucose alarms to better protect against dangerous blood #glucose lows and highs: https://t.co/03ikXotiOq #CGM #ENDO2023 (3/3)
-
Our #Hormones and #Technology News Conference also covers a meta-analysis on closed-loop #insulin delivery systems designed to automate aspects of #diabetes management in children and teen: https://t.co/03ikXotiOq #ENDO2023 (2/3)
-
-
Mashup Score: 1Afternoon exercise linked to greatest HbA1c reduction in type 2 diabetes - 10 month(s) ago
Physical activity performed in the afternoon could yield a greater reduction in HbA1c than physical activity during other times in the day, according to an analysis of data from the Look AHEAD trial published in Diabetes Care. “This is the first large-scale epidemiological study demonstrating that timing of unsupervised physical activity is associated with long-term improvement in blood
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet
Linked Comment by André J Scheen: Pragmatic trials, a step forward to assess #cardiovascular efficacy of new #glucose-lowering agents https://t.co/sEkIbYq9Fe #T2D